Eric Venker, President and Immunovant CEO at Roivant Sciences Ltd., filed a Form 4 on October 30, 2026, disclosing the sale of 200,000 common shares on October 28, 2026, under a pre-established Rule 10b5-1 trading plan.

Key Highlights

  • Shares sold: 200,000 common shares of Roivant Sciences Ltd. were disposed of on October 28, 2026.
  • Weighted average price: The reported sale price was $36.59 per share, a weighted average across multiple transactions ranging from $36.18 to $36.95, inclusive.
  • Remaining ownership: Following the transaction, Venker directly beneficially owned 1,199,154 common shares.
  • 10b5-1 plan: The sales were made pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026.
  • Reporting person role: Eric Venker is identified in the filing as an officer with the title President and Immunovant CEO.

Venker's October 2026 Share Disposition Under 10b5-1 Plan

According to the filing, Eric Venker, an officer of Roivant Sciences Ltd. (NASDAQ:ROIV) serving as President and Immunovant CEO, disposed of 200,000 common shares on October 28, 2026. The transaction code reported is "S," indicating a sale. The filing notes that the shares were sold in multiple transactions, with prices ranging from $36.18 to $36.95 per share, inclusive, and that the price of $36.59 listed in the filing represents a weighted average.

The filing states that the sales were effected pursuant to a Rule 10b5-1 trading plan that Venker adopted on June 30, 2026. The filing also confirms that the Form 4 was checked to indicate the transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). According to the filing, Venker undertakes to provide full information regarding the number of common shares sold at each separate price within the range, upon request by the issuer, any security holder, or the SEC staff.

Following the reported transaction, the filing discloses that Venker directly beneficially owned 1,199,154 common shares. No derivative securities transactions were reported in Table II. The Form 4 was signed by Sam Kaplan as attorney-in-fact for Eric Venker and dated October 30, 2026.

What Was Disclosed

Roivant Sciences Ltd. officer Eric Venker disclosed the sale of 200,000 common shares on October 28, 2026, at a weighted average price of $36.59, executed under a Rule 10b5-1 plan adopted June 30, 2026, leaving him with 1,199,154 directly held shares.